Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 113; no. 23; pp. 6544 - 6549
• Main Authors: Li, Wen, Englund, Elisabet, Widner, Ha°kan, Mattsson, Bengt, van Westen, Danielle, Lätt, Jimmy, Rehncrona, Stig, Brundin, Patrik, Björklund, Anders, Lindvall, Olle, Li, Jia-Yi
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 07.06.2016
• Series: From the Cover
• Subjects: alpha-Synuclein; Biological Sciences; Brain; Cells; Clinical Medicine; Corpus Striatum; Dopamine; Fetal Tissue Transplantation; Humans; Immune response; Klinisk medicin; Medical and Health Sciences; Medicin och hälsovetenskap; Mesencephalon - embryology; Neurologi; Neurology; Neurons; Parkinson Disease; Parkinson's disease; Pathology; Putamen; Tomography; Transplantation; Transplants & implants; synucleinopathy; reinnervation; autopsy; Parkinson’s disease; transplantation
• ISSN: 0027-8424; 1091-6490; 1091-6490
• DOI: 10.1073/pnas.1605245113

Clinical trials using cells derived from embryonic ventral mesencephalon have shown that transplanted dopaminergic neurons can survive and function in the long term, as demonstrated by in vivo brain imaging using 18F-fluorodopa and 11C-raclopride positron emission tomography. Here we report the postmortem analysis of a patient with Parkinson’s disease who 24 y earlier underwent unilateral transplantation of embryonic dopaminergic neurons in the putamen and subsequently exhibited major motor improvement and recovery of striatal dopaminergic function. Histopathological analysis showed that a dense, near-normal graft-derived dopaminergic reinnervation of the putamen can be maintained for a quarter of a century despite severe host brain pathology and with no evidence of immune response. In addition, ubiquitin- and α-synuclein–positive inclusions were seen, some with the appearance of typical Lewy bodies, in 11–12% of the grafted dopaminergic neurons, reflecting the spread of pathology from the host brain to the transplants. Because the clinical benefits induced by transplantation in this patient were gradually lost after 14 y posttransplantation, our findings provide the first reported evidence, to our knowledge, that even a viable dopaminergic graft giving rise to extensive striatal reinnervation may lose its efficacy if widespread degenerative changes develop in the host brain.